Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established treatments for type 2 diabetes.
• These agents demonstrate significant cardiovascular protective effects, particularly in reducing heart failure events.
• Their benefits are observed across various patient subgroups, including those with reduced kidney function and heart failure without diabetes.

Purpose of the Study:

• To review the cardiovascular outcome benefits of SGLT2 inhibitors.
• To explore the potential expansion of SGLT2 inhibitor use in chronic kidney disease (CKD) patients without diabetes.
• To summarize current evidence on MACE reduction and heart failure prevention by SGLT2 inhibitors.

Main Methods:

• Review of clinical trial data and published literature on SGLT2 inhibitors.
• Analysis of cardiovascular and renal outcomes in diverse patient populations.
• Evaluation of safety profiles and emerging indications for SGLT2 inhibitors.

Main Results:

• SGLT2 inhibitors reduce cardiovascular events, notably heart failure hospitalizations, in patients with type 2 diabetes.
• Major adverse cardiovascular event (MACE) reductions are primarily seen in patients with pre-existing cardiovascular disease.
• Benefits extend to patients with type 2 diabetes and eGFR down to 30 mL/min/1.73 m², and to patients with heart failure without diabetes.

Conclusions:

• SGLT2 inhibitors offer substantial cardiovascular and heart failure benefits in patients with type 2 diabetes and CKD.
• Ongoing research investigates their efficacy in non-diabetic CKD patients.
• Wider use of SGLT2 inhibitors in CKD patients to mitigate cardiovascular risk is anticipated, despite some safety considerations.